CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancers of the central nervous system, with Berubicin and TPI 287 as its core programs. The company does not yet generate commercial product revenue and is funded primarily through equity financing while it advances clinical trials. Berubicin is being developed for malignant gliomas, and TPI 287 is a brain-penetrant taxane derivative being positioned for CNS tumors and other difficult-to-treat cancers. CNS Pharmaceuticals is still in the development and financing phase, so its value proposition depends on clinical progress, regulatory milestones, and the ability to secure additional capital.

1.98

1.98

— CNS Pharmaceuticals, Inc.
%
Investigational oncology drug candidates100% Clinical-stage drug programs aimed at treating malignant gliomas and other CNS cancers.
Drug development and regulatory advancement0% Pre-commercial development activities including clinical trials, manufacturing, and FDA-related work.

CNS Pharmaceuticals does not sell approved medicines to end customers today; instead, its primary stakeholders are...

  • Clinical trial patientsprimary

    Patients with malignant gliomas or other CNS cancers who participate in studies of Berubicin or TPI 287.

  • Clinical investigators and trial sitesprimary

    Hospitals, research centers, and investigators that conduct the company’s trials and generate efficacy/safety data.

  • Future oncology prescriberssecondary

    Neuro-oncologists and cancer specialists who would prescribe the drugs if they are approved.

  • Future hospital and specialty distribution channelsemerging

    Hospitals and specialty channels that would purchase approved rare oncology therapies for inpatient or outpatient use.

CNS Pharmaceuticals is headquartered in the United States and is listed on Nasdaq Capital Market, so its financing,...

  • •United States is the core operating and regulatory market
  • •Nasdaq Capital Market listing ties the company to U.S. capital markets
  • •FDA orphan-drug pathway is central to Berubicin and TPI 287
  • •TPI 287 license covers the United States, Canada, Mexico, and Japan
  • •No commercial revenue geography is disclosed because the company is pre-revenue

The company’s strategy is to advance Berubicin and TPI 287 through clinical development while preserving and extending...

01
Complete Berubicin development milestonesshort-term

Clinical readouts and final analysis are needed to determine whether the asset can progress toward regulatory filing or partnering.

02
Initiate TPI 287 clinical trialshort-term

TPI 287 is the company’s second core asset and a key source of future pipeline value, but it requires substantial funding.

03
Secure additional financingshort-term

The company has no committed funding for later-stage development and must raise capital to continue operations and trials.

04
Strengthen intellectual property protectionmedium-term

Patent and orphan-drug protections are critical for a small biotech with a concentrated pipeline and no commercial revenue.

The company faces substantial development-stage risk because its value depends on a small number of investigational...

critical

Clinical development failure

The company depends on Berubicin and TPI 287 advancing successfully through trials and regulatory review.

Scope
Berubicin and TPI 287 pipeline
Materiality
high
high

Financing and dilution risk

Management states that significant additional capital will be required and there are no committed financing sources.

Scope
Equity sales, debt issuance, ATM program
Materiality
high
high

Nasdaq listing compliance

The company has previously been out of compliance with bid price and equity requirements, and future non-compliance could trigger delisting.

Scope
Nasdaq Capital Market listing
Materiality
high
medium

Regulatory and orphan-drug exclusivity risk

Orphan designation helps but does not guarantee approval or exclusivity if a competitor shows clinical superiority.

Scope
FDA approval pathway
Materiality
medium
Clinical trial cost accruals
R&D expense and operating cash flow
Milestone and license obligations
Liquidity and future expense recognition
Equity issuance and dilution
Per-share metrics and capital structure

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

CNBX Pharmaceuticals Inc.

CNBX · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM · Pharmaceutical Preparations

Corbus Pharmaceuticals Holdings, Inc.

CRBP · Pharmaceutical Preparations

ClearPoint Neuro, Inc.

CLPT · Surgical & Medical Instruments & Apparatus

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

: 11/08/2026